Merchavia Holdings And Investments Ltd · TASE:MRHL
Merchavia Holdings And Investments — Investor Presentation (January 2026)
20 slides from Merchavia Holdings And Investments's investor presentation, January 2026
Slide 1: Life Sciences. A Massive Market Opportunity with Meaningful Impact
Life Sciences. A Massive Market Opportunity with Meaningful Impact 1
Slide 2: Disclaimer
Disclaimer: This presentation (the "Presentation") is for informational purposes only and does not constitute, and shall not form part of, any offer to sell or issue, or any solicitation of an offer to buy or subscribe for, any shares or other securities of Merchavia Holdings and Investments Ltd. (t
Slide 3: About Merchavia - A Public Investment Platform Focused on Life Sciences and MedTech
About Merchavia - A Public Investment Platform Focused on Life Sciences and MedTech Merchavia is a publicly traded investment company, focused on identifying, investing in, and supporting innovative life sciences and medical technology companies. Our Focus Our Approach Our Advantage • Clinically val
Slide 4: Management team
Management team Experienced Leadership Team with a combined background in the fields of capital markets and life sciences. Eli Arad Rani Lifshitz Ilan Goldstein Shmulik Genzel Chief Executive Officer Chairman of the Board President Director • Attorney and economist. • Major shareholder in the • Exte
Slide 5: Scientific Advisory Committee
Scientific Advisory Committee Global expertise and strong international networks Dr. Arnon Chait USA Founder and CEO of Cleveland Diagnostics, Inc. with over 25 years of experience at NASA. Founded and led biomed companies, research companies and companies engaged in optical electronics. Dr. Mark St
Slide 6: Life Sciences – A Rapidly Expanding Global Market
Life Sciences – A Rapidly Expanding Global Market Global Medical Devices Market (2025) $586B The medical device market is expected to grow at a CAGR of 6.1% from 2026-2034 $1.02T Global Digital Health Market (2025) $347B The market is expected to grow at a CAGR of 17.2% and is anticipated to reach i
Slide 7: Aging is the most significant risk factor for cancer and chronic diseases
AGING IS THE MOST SIGNIFICANT RISK FACTOR FOR CANCER AND CHRONIC DISEASES 7
Slide 8: Cancer incidence increases sharply with age
Cancer incidence increases sharply with age 25 350 1,000 cases per 100,000 cases per 100,000 cases per 100,000 under age 20 at ages 45–49 at age 60 years + 8 Sources: www.cancer.gov
Slide 9: The risk of cancer and heart attacks is 40 times higher
The risk of cancer and heart attacks at age 60 is 40 times higher than at age 20 9 Sources: www.cancer.gov Nortonhealthcare.com
Slide 10: The Digital Transformation of Healthcare
The Digital Transformation of Healthcare Rising economic burden on global healthcare systems Early detection is critical to managing chronic and life- threatening diseases Technology-driven solutions enable scalable, cost- The Result: effective care Accelerated innovation across diagnostics, monitor
Slide 11: Identifying the right opportunities at the right time leads to success
Identifying the right opportunities at the right time leads to success Identifying companies Huge business potential Significant value increase with low technological risk 11
Slide 12: Merchavia’s Investment Philosophy - guerrilla investments
Merchavia’s Investment Philosophy- guerrilla investments • Identifying the right opportunities at the right stage • Focus on companies with low technological risk and clinical validation • Large addressable markets with strong value-creation potential • Active involvement to drive milestones and val
Slide 13: Proven Execution and Growing Portfolio
Proven Execution and Growing Portfolio 1 First exit: RMDY merged with OPRX (Nasdaq-listed) 4 4 Portfolio companies Raised a combined $98M over the past two years* 259 Aggregate last-round valuations: $259M** 13*13 Most of the amount relates to CDX, the remainder in EFA, Nervio and CardiacSense. ** F
Slide 14: ClevelandDx - Protein Structure-Based Cancer Diagnostics
ClevelandDx - Protein Structure-Based Cancer Diagnostics ClevelandDx is a clinical-stage diagnostics company developing a proprietary protein-structure–based diagnostic platform, IsoClear™, which captures disease biology beyond traditional concentration-based assays. The IsoClear™ platform supports
Slide 15: CardiacSense - From R&D to Global Commercial Scale
CardiacSense - From R&D to Global Commercial Scale. One of the leading medical-grade wearable solutions for continuous, non-invasive Blood Pressure & Arrhythmia monitoring. MILESTONE Strategic Partnership - Chip co-development and manufacturing collaboration with leading European semiconductor globa
Slide 16: EFA – RevDx | Portable AI-Based Hematology Diagnostics
EFA – RevDx | Portable AI-Based Hematology Diagnostics EFA has developed RevDx, the world's first fully autonomous, portable point-of-care platform for hematology diagnostics, enabling lab-quality blood tests from a simple finger prick. The solution decentralizes core hematology testing, significant
Slide 17: Nervio - AI-Driven Neuromonitoring Platform
Nervio - AI-Driven Neuromonitoring Platform Nervio is developing a first-in-class AI-driven neuromonitoring platform, designed to improve surgical safety while significantly reducing the cost and complexity of intraoperative nerve monitoring. The platform replaces a labor-intensive service model wit
Slide 18: Key Portfolio Milestones - Next 18 Months
Key Portfolio Milestones - Next 18 Months Commercial Expansion: Scaling Initiation and advancement of Commercial Scale-Up: Continued growth CardiacSense Watch v13.0 Launch deployments in Brazil, UK, and Italy FDA 510(k) submission process. of IsoPSA test volumes following FDA (2026): Market introduc
Slide 19: Why Merchavia: We have all the necessary components
Why Merchavia: We have all the necessary components Investments at the right stage, Experienced team with global Proven ability to execute and following technological strategic connections. generate value. validation. 19
Slide 20: Thank you!
20 Thank you! ¢g g MERCHAVIA Invest in Life
Merchavia Holdings and Investments — Investor Presentation (January 2026) on 6ix